Simmiparib 是一种高效且具有口服活性的 PARP1 和 PARP2 抑制剂(IC50 分别为 1.75 nM 和 0.22 nM),其对 PARP1/2 的抑制作用强于母体化合物 Olaparib (MS-Y92542),并在同源重组修复 (HR) 缺陷细胞中通过诱导 DNA 双链断裂 (DSB) 积累和 G2/M 阻滞来诱导细胞凋亡 (apoptosis),在细胞和裸鼠移植瘤模型中均表现出显著的抗癌活性。
产品编号: MS-P80296 纯度: 99.01% CAS No.: 1551355-46-4 分子式: C23H18F4N6O2 分子量: 486.42
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价
(0.1 - 0.2mg)
询价
询价

产品描述

Simmiparib 是一种高效且具有口服活性的 PARP1 和 PARP2 抑制剂(IC50 分别为 1.75 nM 和 0.22 nM),其对 PARP1/2 的抑制作用强于母体化合物 Olaparib (MS-Y92542),并在同源重组修复 (HR) 缺陷细胞中通过诱导 DNA 双链断裂 (DSB) 积累和 G2/M 阻滞来诱导细胞凋亡 (apoptosis),在细胞和裸鼠移植瘤模型中均表现出显著的抗癌活性。

生物实验数据

生物活性 Simmiparib is a potent and orally active PARP1 and PARP2 inhibitor (IC50 = 1.75 nM and 0.22 nM, respectively) that exhibits stronger inhibition of PARP1/2 than its parent compound Olaparib (MS-Y92542), induces apoptosis by promoting DNA double-strand break (DSB) accumulation and G2/M arrest in homologous recombination (HR)-deficient cells, and demonstrates significant anticancer activity in both cellular and nude mouse xenograft models.
IC50 & Target PARP1:0.74 nM, PARP2:0.22 nM
体外研究
(In Vitro)

Simmiparib (0-10 μM; 3 days) exhibits anti-proliferative activity against various cancer cells.
Simmiparib (0-10 μM; 48 h) induces typical G2/M arrest in Capan-1 cells.
Simmiparib (0.1-2 μM; 24 h) induces apoptosis in MDA-MB-436 and V-C8 (BRCA2-/-) cells, and increases dose-dependently the levels of γH2AX.
Simmiparib (1-10 μM; 48 h or 72 h) increases the phosphorylation levels of Chk1 and Chk2 and the protein levels of p-Cyclin B1 (S147), Cyclin B1, p-CDK1 (Y15) and CDK1.

Cell Proliferation Assay

Cell Line: Various cancer cells harboring deficient BRCA1, BRCA2, PTEN and EWS-FLI1
Concentration: 0-10 μM
Incubation Time: 3 days
Result: Exhibited anti-proliferative activity against MDA-MB-436 (BRCA1-/-), RD-ES (EWS-FLI1), DoTc2-4510 (BRCA2-/-), Capan-1 (BRCA2-/-) and U251 (PTEN-/-) with IC50s of 0.2 nM, 4.6 nM, 20 nM, 21 nM and 36 nM, respectively.

Cell Cycle Analysis

Cell Line: Capan-1 cells
Concentration: 0, 1, 3 and 10 μM
Incubation Time: 48 h
Result: Induced typical G2/M arrest in a concentration-dependent manner.

Apoptosis Analysis

Cell Line: MDA-MB-436
Concentration: 0.1 and 1 μM
Incubation Time: 24 h
Result: Led to 39.64% and 42.98% apoptosis at 0.1 and 1 μM, respectively.
Increased dose-dependently the levels of γH2AX.

Apoptosis Analysis

Cell Line: V-C8 (BRCA2-/-)
Concentration: 0.5 and 2 μM
Incubation Time: 24 h
Result: Caused more than 57% apoptosis.

Western Blot Analysis

Cell Line: Capan-1
Concentration: 1 and 10 μM
Incubation Time: 48 h or 72 h
Result: Increased the phosphorylation levels of Chk1 and Chk2 but did not change the levels of the corresponding total proteins.
Increased the protein levels of p-Cyclin B1 (S147), Cyclin B1, p-CDK1 (Y15) and CDK1.
体内研究
(In Vivo)

Simmiparib (2, 4 and 8 mg/kg; p.o.; qd, for 14 days) inhibits the growth of tumor in V-C8 (BRCA2-/-) and MDA-MB-436 (BRCA2-/-) xenograft mice models.
Simmiparib (10 and 50 mg/kg; p.o.; qd, for 42 days) inhibits the growth of BRCA1-mutated breast cancer in xenograft mice model.

Animal Model: Female BALB/cA nude mice (Subcutaneously injected with BRCA2-/- V-C8 cells and BRCA2-/- MDA-MB-436 cells)
Dosage: 2, 4 and 8 mg/kg
Administration: p.o.; qd, for 14 days
Result: Apparently inhibited the growth of the V-C8 tumor with an inhibition rate of 74.53% at 8 mg/kg.
Suppressed the growth of the BRCA1-deficient MDA-MB-436 xenografts in a dose-dependent manner with its average inhibition rates of 64.93, 82.98 and 85.79% at 2, 4 and 8 mg/kg.
Did not cause significant loss of body weight.
Animal Model: Female BALB/cA nude mice (Subcutaneously injected with cancer cells derived from BRCA1-mutated BR-05-0028 breast cancer tissue)
Dosage: 10 and 50 mg/kg
Administration: p.o.; qd, for 42 days
Result: Elicited dose-dependent growth inhibition with the inhibition rate of 76.73% and 93.82% at 10 mg/kg and 50 mg/kg, respectively.
性状 固体
颜色 White to off-white

化学信息

分子量 486.42
分子式 C23H18F4N6O2
CAS No. 1551355-46-4

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (205.58 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.0558 mL10.2792 mL20.5584 mL51.3959 mL
5 mM0.4112 mL2.0558 mL4.1117 mL10.2792 mL
10 mM0.2056 mL1.0279 mL2.0558 mL5.1396 mL
15 mM0.1371 mL0.6853 mL1.3706 mL3.4264 mL
20 mM0.1028 mL0.5140 mL1.0279 mL2.5698 mL
25 mM0.0822 mL0.4112 mL0.8223 mL2.0558 mL
30 mM0.0685 mL0.3426 mL0.6853 mL1.7132 mL
40 mM0.0514 mL0.2570 mL0.5140 mL1.2849 mL
50 mM0.0411 mL0.2056 mL0.4112 mL1.0279 mL
60 mM0.0343 mL0.1713 mL0.3426 mL0.8566 mL
80 mM0.0257 mL0.1285 mL0.2570 mL0.6424 mL
100 mM0.0206 mL0.1028 mL0.2056 mL0.5140 mL
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础